PCI Noninferior to CABG for Left Main Coronary Artery Disease

This article originally appeared here.
Share this content:
PCI Noninferior to CABG for Left Main Coronary Artery Disease
PCI Noninferior to CABG for Left Main Coronary Artery Disease

MONDAY, Oct. 31, 2016 (HealthDay News) -- For patients with left main coronary artery disease, percutaneous coronary intervention (PCI) with everolimus-eluting stents is noninferior to coronary artery bypass grafting (CABG), according to a study published online Oct. 31 in the New England Journal of Medicine. The research was published to coincide with the Cardiovascular Research Foundation's Transcatheter Cardiovascular Therapeutics 2016 meeting, held from Oct. 29 to Nov. 2 in Washington, D.C.

Gregg W. Stone, M.D., from New York Presbyterian Hospital in New York City, and colleagues randomized 1,905 patients with left main coronary artery disease of low or intermediate anatomical complexity to undergo PCI with fluoropolymer-based cobalt-chromium everolimus-eluting stents (948 patients) or CABG (957 patients).

The researchers found that a primary end point (rate of a composite of death from any cause, stroke, or myocardial infarction at three years) had occurred in 15.4 and 14.7 percent of patients in the PCI and CABG groups, respectively (difference, 0.7 percentage points; P = 0.02 for noninferiority; hazard ratio, 1.00; 95 percent confidence interval, 0.79 to 1.26; P = 0.98 for superiority). The secondary end point event of death, stroke, or myocardial infarction at 30 days occurred in 4.9 and 7.9 percent of patients in the PCI and CABG groups, respectively (P < 0.001 for noninferiority; P = 0.008 for superiority).

"PCI with everolimus-eluting stents was noninferior to CABG with respect to the rate of the composite end point of death, stroke, or myocardial infarction at three years," the authors write.

Several authors disclosed financial ties to biopharmaceutical companies, including Abbott Vascular, which funded the study.

Abstract
Full Text
Editorial
More Information

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

FDA Approves First Drug for Rare Form of Rickets

FDA Approves First Drug for Rare Form of ...

Crysvita approved for adults and children ages 1 year and older with x-linked hypophosphatemia

High FGF-23 Linked to Recurrent Cardiac Events After ACS

High FGF-23 Linked to Recurrent Cardiac Events After ...

FGF-23 in top quartile independently linked to greater risk of CV death, heart failure hospitalization

Medical Cannabis Not Recommended for Sleep Apnea

Medical Cannabis Not Recommended for Sleep Apnea

American Academy of Sleep Medicine says evidence insufficient to recommend cannabis for apnea

is free, fast, and customized just for you!

Already a member?

Sign In Now »